Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the triple combination of Carboplatin,
Paclitaxel and Topotecan has a superior clinical outcome in the treatment of ovarian cancer
compared with the combination of Carboplatin and Paclitaxel.